P/B
2,5
Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
$3.5B
Market Cap • 9/22/2026
2006
(20 years)
Founded
2013
(13 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
6,2
P/EBITDA
27,5
P/OCF
19,5
P/FCF
21
P/E
30,8
BVPS
17,1
EPS
1,4
Market Cap
Market Cap
3,5B
EV
3B
EV/Revenue
5,4
EV/EBITDA
24
EV/EBIT
28,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-323,4M
Profitability
Gross Margin
71,7%
EBITDA Margin
22,5%
EBIT Margin
18,8%
Net Margin
20,4%
D&A/EBITDA
1,8%
R&D/Revenue
16,6%
Capex/Revenue
2,2%
Capex/D&A
59,5%
Capex/OCF
6,9%
SBC/OCF
27,2%
% PPE
3,8%
% Goodwill
51,6%
ROE
8,8%
ROIC
11%
Growth
CAGR Revenue 5Y
29%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
9,2
Quick Ratio
8,6
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!